JP2016540021A5 - - Google Patents

Download PDF

Info

Publication number
JP2016540021A5
JP2016540021A5 JP2016539161A JP2016539161A JP2016540021A5 JP 2016540021 A5 JP2016540021 A5 JP 2016540021A5 JP 2016539161 A JP2016539161 A JP 2016539161A JP 2016539161 A JP2016539161 A JP 2016539161A JP 2016540021 A5 JP2016540021 A5 JP 2016540021A5
Authority
JP
Japan
Prior art keywords
dosage form
unit dosage
solid unit
solid
form according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016539161A
Other languages
English (en)
Japanese (ja)
Other versions
JP6447931B2 (ja
JP2016540021A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/077127 external-priority patent/WO2015086643A1/en
Publication of JP2016540021A publication Critical patent/JP2016540021A/ja
Publication of JP2016540021A5 publication Critical patent/JP2016540021A5/ja
Application granted granted Critical
Publication of JP6447931B2 publication Critical patent/JP6447931B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016539161A 2013-12-12 2014-12-10 エステトロール成分を含有する口腔内崩壊固体単位剤形 Expired - Fee Related JP6447931B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13196904.0 2013-12-12
EP13196904 2013-12-12
PCT/EP2014/077127 WO2015086643A1 (en) 2013-12-12 2014-12-10 Orally disintegrating solid dosage unit containing an estetrol component

Publications (3)

Publication Number Publication Date
JP2016540021A JP2016540021A (ja) 2016-12-22
JP2016540021A5 true JP2016540021A5 (2) 2018-01-25
JP6447931B2 JP6447931B2 (ja) 2019-01-09

Family

ID=49759137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016539161A Expired - Fee Related JP6447931B2 (ja) 2013-12-12 2014-12-10 エステトロール成分を含有する口腔内崩壊固体単位剤形

Country Status (30)

Country Link
US (2) US9884064B2 (2)
EP (1) EP3079671B1 (2)
JP (1) JP6447931B2 (2)
KR (1) KR102265150B1 (2)
CN (1) CN105979935B (2)
AU (1) AU2014363599B2 (2)
BR (1) BR112016013502B1 (2)
CA (1) CA2932855C (2)
CL (1) CL2016001411A1 (2)
CY (1) CY1119817T1 (2)
DK (1) DK3079671T3 (2)
EA (1) EA032306B1 (2)
ES (1) ES2655076T3 (2)
HR (1) HRP20180129T1 (2)
HU (1) HUE035848T2 (2)
IL (1) IL246082B (2)
LT (1) LT3079671T (2)
MA (1) MA39105B1 (2)
MX (1) MX369035B (2)
NO (1) NO3079671T3 (2)
NZ (1) NZ720906A (2)
PL (1) PL3079671T3 (2)
PT (1) PT3079671T (2)
RS (1) RS56738B1 (2)
SG (1) SG11201604741UA (2)
SI (1) SI3079671T1 (2)
SM (1) SMT201700582T1 (2)
TN (1) TN2016000230A1 (2)
WO (1) WO2015086643A1 (2)
ZA (1) ZA201603903B (2)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2714712T (pt) 2011-06-01 2016-11-08 Estetra Sprl Processo para a produção de intermediários de estetrol
SG195118A1 (en) 2011-06-01 2013-12-30 Estetra S A Process for the production of estetrol intermediates
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
PL2741824T3 (pl) * 2011-08-11 2018-03-30 Estetra S.P.R.L. Zastosowanie estetrolu jako środka antykoncepcji awaryjnej
DK3701944T3 (da) * 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
LT3310346T (lt) 2015-06-18 2021-06-10 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
LT3310345T (lt) * 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CR20180042A (es) 2015-06-18 2018-05-03 Mithra Pharmaceuticals S A Unidad de dosificación orodispersable que contiene un componente estetrol.
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
US20200046729A1 (en) * 2016-08-05 2020-02-13 Estetra Sprl Methods using combined oral contraceptive compositions with reduced cardiovascular effects
SG11202007163WA (en) * 2018-02-07 2020-08-28 Estetra Sprl Contraceptive composition with reduced cardiovascular effects
TWI801561B (zh) * 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
CN111989105B (zh) * 2018-04-19 2024-07-19 埃斯特拉私人有限责任公司 化合物以及它们在缓解绝经相关症状中的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
GB2603868B (en) * 2019-09-27 2023-10-11 Ind Chimica Srl Process for preparing (15ALPHA,16ALPHA,17BETA)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-tetrol monohydrate (estetrol monohydrate) and intermediates of said process
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
CN113552768B (zh) 2020-04-24 2025-06-17 爱天思株式会社 感光性着色组合物、彩色滤光片及图像显示装置
US20230346695A1 (en) 2020-09-29 2023-11-02 Millicent Pharma Limited Orodispersible formulations
AU2023428138A1 (en) 2023-02-02 2025-09-04 Industriale Chimica S.R.L. PROCESS FOR PREPARING (15α,16α,17β)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL (ESTETROL) MONOHYDRATE
TW202533830A (zh) 2024-02-28 2025-09-01 比利時商埃斯特拉有限公司 雌四醇多晶型及其生產
HUP2400151A1 (hu) 2024-02-28 2025-09-28 Richter Gedeon Nyrt Ösztetrol-monohidrát kristályosítási eljárás

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
PT1390040E (pt) 2001-05-18 2007-04-30 Pantarhei Bioscience Bv Composição farmacêutica para ser utilizado na terapia hormonal de substituição.
EP1390042B1 (en) 2001-05-23 2007-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
ES2337129T3 (es) 2001-05-23 2010-04-21 Pantarhei Bioscience B.V. Sistema de administracion de medicamento comprendiendo un estrogeno tetrahidroxilado para el uso en la anticoncepcion hormonal.
WO2003018026A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US8026228B2 (en) 2001-11-15 2011-09-27 Pantarhei Bioscience B.V. Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
DE60215224T2 (de) * 2002-02-21 2007-08-23 Schering Aktiengesellschaft Pharmazeutische zusammensetzung, enthaltend ein oder mehrere steroide, eine oder mehrere tetrahydrofolatverbindungen und vitamin b12
GB0410616D0 (en) 2004-05-13 2004-06-16 Unilever Plc Antiperspirant or deodorant compositions
US20070048369A1 (en) 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
WO2007081206A1 (en) 2006-01-09 2007-07-19 Pantarhei Bioscience B.V. A method of treating an acute vascular disorder
US20070286819A1 (en) * 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
SG174785A1 (en) * 2006-06-08 2011-10-28 Warner Chilcott Co Llc Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty
TW200831139A (en) * 2006-11-29 2008-08-01 Wyeth Corp Estrogen/SERM and estrogen/progestin bi-layer tablets
WO2008079245A2 (en) * 2006-12-20 2008-07-03 Duramed Pharmaceuticals, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
CN101631536A (zh) * 2007-01-12 2010-01-20 惠氏公司 片中片组合物
EP2155205B1 (en) 2007-06-21 2011-12-21 Pantarhei Bioscience B.V. Treatment of meconium aspiration syndrome with estrogens
US20110250274A1 (en) 2008-09-19 2011-10-13 Shaked Ze Ev Estriol formulations
DE102009007771B4 (de) * 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
CN102058604A (zh) * 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
WO2014159377A1 (en) 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens

Similar Documents

Publication Publication Date Title
JP2016540021A5 (2)
AU2014363599B2 (en) Orally disintegrating solid dosage unit containing an estetrol component
HRP20210555T1 (hr) Orodisperzibilna tableta koja sadrži estetrol
HRP20220332T1 (hr) Farmaceutski pripravak koji sadrži drospirenon za uporabu kao kontraceptiv
JP2018521985A5 (2)
TW200803857A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
JP2015038135A5 (2)
JP2018517718A5 (2)
JP2010522137A5 (2)
JP2015523407A5 (2)
JP2013529665A5 (2)
JP2008543758A5 (2)
HRP20131088T1 (hr) Äśvrsti farmaceutski pripravci s fiksnom dozom koji sadrže irbesartan i amlodipin, njihova priprava i terapijska primjena
JP2014221827A5 (2)
RU2016117186A (ru) Комбинированная композиция, содержащая тадалафил и амлодипин
JP2022552187A5 (2)
RU2015132902A (ru) Новый быстрорастворимый состав гранул с улучшенной растворимостью
CN104706604A (zh) 一种吡仑帕奈冻干口崩片及其制备方法
JP2016505050A5 (2)
JP2015120758A5 (2)
CN101015519B (zh) 一种氯雷他定口服复方药物组合物
RU2020120156A (ru) Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена
WO2014040524A1 (zh) 3-正丁基异吲哚啉酮在制备预防和治疗脑梗塞的药物中的应用
JP2019535830A5 (2)
RU2016127361A (ru) Гастроретентивные фармацевтические композиции для перорального введения